YM 529

inhibits osteoclastic bone resorption; structure given in first source

Also Known As:

(1-hydroxy-2-(imidazo(1,2-a)-pyridin-3-yl)ethylidene)bisphosphonic acid monohydrate; 1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid monohydrate; ONO-5920; Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-; YH 529; YH-529; YH529; YM-529; YM529; minodronate; minodronic acid hydrate

Networked: 109 relevant articles (26 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hagino, Hiroshi: 8 articles (07/2021 - 06/2009)
2.	Nakamura, Toshitaka: 6 articles (07/2021 - 03/2005)
3.	Fukunaga, Masao: 5 articles (11/2020 - 01/2009)
4.	Matsumoto, Toshio: 5 articles (07/2020 - 06/2009)
5.	Nishida, Shozo: 5 articles (03/2012 - 01/2003)
6.	Sone, Teruki: 4 articles (07/2021 - 06/2009)
7.	Shiraki, Masataka: 4 articles (11/2020 - 06/2009)
8.	Matsuyama, Yukihiro: 4 articles (03/2019 - 07/2016)
9.	Ohishi, Tsuyoshi: 4 articles (03/2019 - 07/2016)
10.	Tsubaki, Masanobu: 4 articles (03/2012 - 10/2003)

Related Diseases

1.	Osteoporosis 01/01/2010 - "Daily oral minodronate was safe, well tolerated and effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis. " 08/01/2009 - "Daily oral minodronate is safe, well-tolerated, and is effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis." 10/02/2020 - "The goal of this study was to review relevant randomized controlled trials or case-control studies to determine the clinical efficacy of minodronate in the treatment of osteoporosis. " 01/01/2018 - "More clinical studies on minodronate and its use in osteoporosis treatment, with a large number of subjects, should be conducted to verify hip fracture risk reduction and long-term results." 09/01/2013 - "Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial."
2.	Neoplasm Metastasis (Metastasis) 08/01/2015 - "Combined treatment with YM529 and IFN-α may be beneficial in patients with human RCC bone metastasis. " 01/01/2003 - "In addition, treatment with YM529 after establishment of bone metastasis (on day 21) also inhibited bone metastasis, although the treatment was more effective when started earlier. " 03/15/2012 - "We found that YM529/ONO-5920 significantly inhibited metastasis, cell migration, invasion, and adhesion at concentrations that did not have antiproliferative effects on LM8 cells. " 10/01/2010 - "These findings suggest that YM529/ONO-5920 has potential clinical applications for the treatment of tumour cell metastasis." 10/01/2010 - "The results indicate that YM529/ONO-5920 suppresses the Rho/ROCK pathways, thereby inhibiting B16BL6 cell migration, invasion, adhesion and metastasis. "
3.	Neoplasms (Cancer) 08/08/2007 - "These results suggest that YM529 is a potent therapeutic agent for human breast cancers, activating the mitochondria-dependent apoptotic pathway through the inhibition of protein farnesylation." 01/12/2007 - "Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC." 06/01/2006 - "The purpose of this study was to investigate the antitumor effects of newly developed minodronate (MIN) on a variety of human malignant bone tumors. " 08/01/2015 - "Neither YM529 nor IFN-α alone significantly inhibited the growth of established bone metastatic tumors. " 05/01/2009 - "YM529 inhibited tumor cell migration induced by HGF and this effect was reduced by co-treatment with GGOH. "
4.	Postmenopausal Osteoporosis 05/25/2022 - "Conclusion: Minodronate is effective and safe in the treatment of postmenopausal osteoporosis without severe side effects. " 07/01/2012 - "The objective of this study was to determine the safety and efficacy of long-term minodronate treatment in women with postmenopausal osteoporosis based on re-analysis of a phase III 2-year clinical trial with a 1-year extension. " 07/01/2012 - "Three years of treatment with minodronate in patients with postmenopausal osteoporosis." 05/01/2010 - "Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis." 01/01/2017 - "The purpose of this study was to investigate the efficacy of switching raloxifene with minodronate in patients who responded poorly to the treatment of postmenopausal osteoporosis with raloxifene. "
5.	Hip Fractures (Intertrochanteric Fractures) 07/01/2016 - "The aim of this study was to investigate the efficacy of monthly minodronate therapy (50 mg/4 wk) for preventing bone loss over a 9-mo period following hip fractures. " 07/01/2016 - "Monthly minodronate therapy during the early stages after hip fractures has favorable effects on restoring overall lumbar BMD and contralateral femoral neck BMD in patients with independent mobility prior to fractures." 09/01/2013 - "Non-vertebral fractures occurred in 5 patients in the minodronate group and 7 patients in the risedronate group (5 hip fractures; one fracture each at the distal forearm and pelvis). " 03/01/2010 - "In postmenopausal women with osteoporosis, alendronate, risedronate, minodronate, and raloxifene are effective in preventing vertebral fractures, and alendronate and risedronate significantly prevent hip fractures. " 01/01/2012 - "In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk."

Related Drugs and Biologics

1.	Diphosphonates (Bisphosphonates)
2.	Alendronate (Alendronate Sodium)
3.	Risedronic Acid (Actonel)
4.	Raloxifene Hydrochloride (Evista)
5.	Nitrogen
6.	Glucocorticoids
7.	Calcitonin (Calcitonin, Eel)
8.	Docetaxel (Taxotere)
9.	elcatonin
10.	Etidronic Acid (HEDP)

Related Therapies and Procedures

1.	Therapeutics
2.	Gastrectomy
3.	Subcutaneous Injections
4.	Aftercare (After-Treatment)
5.	Intravenous Injections